Report Materials
EXECUTIVE SUMMARY:
The objective of this review was to assess whether Kaiser properly valued and reported the prescription drug additional benefit in the Calendar Year 2000 Adjusted Community Rate Proposal. Our review found that Kaiser paid less than the average manufacturer price for the prescription drugs we reviewed and, therefore, properly valued those drugs. Additionally, we found the prescription drug additional benefit reported in the Calendar Year 2000 Adjusted Community Rate Proposal was properly based on actual costs.
-
-
-
Notice
This report may be subject to section 5274 of the National Defense Authorization Act Fiscal Year 2023, 117 Pub. L. 263.
.png){kind=logo}